Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... AVIV, Israel, May 6 InspireMD, developers of,MGuard(TM), announced ... the,iMOS registry. MGuard(TM) was successfully implanted at the General,University ... Jan Horak. , InspireMD plans ... is a post market study, will be conducted in ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the first quarter ended March 31, 2009, and provided ... pivotal Phase 3 SPEAR trial of picoplatin for the ...
Cached Medicine Technology:InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9
(Date:7/11/2014)... AngelWeddingDress is now providing worldwide clients ... collections ”. When it comes to buying summer wedding ... with the unlimited stock of beautiful wedding gowns. Recently, ... wonderful summer wedding gowns. , The company’s current ... keep pace with the newest fashion trends. The top ...
(Date:7/11/2014)... July 11, 2014 Shoulder instability is ... of return to play has not been regularly determined ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... is approximately 90 percent no matter what the stabilization ... success rate of return to play following shoulder stabilization ...
(Date:7/11/2014)... SEATTLE, WA Re-tearing a repaired knee Anterior Cruciate ... study being presented today at the American Orthopaedic Society ... and patient education regarding modifiable risk factors may minimize ... "Our research suggests that a few risk factors such ... may point to the possibility of re-injury," said lead ...
(Date:7/11/2014)... Austin, TX (PRWEB) July 11, 2014 ... with their customers and to show more about their ... http://www.kennrenner.com/buyaveryranch/ and view their home videos online, ... , Avery Ranch is Austin, Texas’ premiere golf course ... the city limits of Austin. Avery Ranch features an ...
(Date:7/11/2014)... Wearing the school motto on their shirts, ... staff came together this past Saturday morning ready to wave, ... the Homer Township Independence Day Parade. The theme of ... , Everest community recognized the theme of A Salute ... and blue. The blue Everest balloons filled with helium ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:Avery Ranch Announces Their New Website to Better Connect with Customers 2Health News:Everest Academy Participates in the Homer Township Independence Day Parade 2
... (OTC,Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of ... has,changed to CHRX from PMQC. The Company,s common stock ... About Chem Rx Corporation, Founded more than ... of institutional pharmacy services in the New York City,metropolitan ...
... monitor/defibrillators help ensure safety at 112th ... Royal Philips,Electronics (NYSE: PHG , AEX: PHI) ... automated external defibrillators (AEDs) and advanced life,support (ALS) ... run on April 21. The strategic deployment of ...
... 18 Ferring Pharmaceuticals Inc.,has announced that its ... serve as the sponsor for masters track club,Sprint ... commitment to active aging," said,Alex Drigan, Product Director, ... of track and believe that they can inspire ...
... April 18 Chronic pain in the ball ... Metatarsalgia ( http://www.OurHealthNetwork.com/metatarsalgia ) is a,catch-all term ... dropped metatarsal heads, bursitis, arthritis, sesamoiditis, and,Morton,s neuroma. ... each step for them a nightmare., When ...
... density affects memory and psychomotor speed, study says , , ... solvents in products such as paints and dry cleaning ... report. , These abnormalities play a role in ... team conclude in the April issue of the ...
... PROTECTION IN A SUNSCREEN WITH ... MEXORYL(TM) SX, ... worldwide, announces the FDA approval,of ANTHELIOS 40 with the highest photostable UVA ... is a,revolutionary outdoor use sunscreen for the face and body, specifically,tested for ...
Cached Medicine News:Health News:Chem Rx Corporation Changes Ticker Symbol to CHRX 2Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 2Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 3Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 4Health News:Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club 2Health News:Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club 3Health News:Metatarsalgia (or Forefoot Pain) Affects Millions of Americans; Podiatrists Discuss How to Relieve Metatarsalgia Pain 2Health News:Chronic Exposure to Solvents Disturbs Brain's Wiring 2Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 2Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 3Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 4
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: